Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Treasury Shares (2016 - 2024)

Historic Treasury Shares for Rhythm Pharmaceuticals (RYTM) over the last 6 years, with Q4 2024 value amounting to $1.8 million.

  • Rhythm Pharmaceuticals' Treasury Shares rose 6537.18% to $1.8 million in Q4 2024 from the same period last year, while for Dec 2024 it was $1.8 million, marking a year-over-year increase of 6537.18%. This contributed to the annual value of $1.8 million for FY2024, which is 6537.18% up from last year.
  • Rhythm Pharmaceuticals' Treasury Shares amounted to $1.8 million in Q4 2024, which was up 6537.18% from $1.1 million recorded in Q4 2023.
  • Rhythm Pharmaceuticals' Treasury Shares' 5-year high stood at $1.8 million during Q4 2024, with a 5-year trough of $804797.0 in Q4 2022.
  • For the 4-year period, Rhythm Pharmaceuticals' Treasury Shares averaged around $1.2 million, with its median value being $1.0 million (2021).
  • In the last 5 years, Rhythm Pharmaceuticals' Treasury Shares tumbled by 1582.9% in 2022 and then skyrocketed by 6537.18% in 2024.
  • Rhythm Pharmaceuticals' Treasury Shares (Quarter) stood at $956145.0 in 2021, then decreased by 15.83% to $804797.0 in 2022, then surged by 37.25% to $1.1 million in 2023, then soared by 65.37% to $1.8 million in 2024.
  • Its Treasury Shares was $1.8 million in Q4 2024, compared to $1.1 million in Q4 2023 and $804797.0 in Q4 2022.